Physicians in China See Most Significant Demand for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Physicians in China See Most Significant Demand for MabThera Biosimilar

SHANGHAI, China, Dec. 22, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Physicians in China are most eagerly awaiting a biosimilar for MabThera (rituximab) for the treatment of non-Hodgkin's lymphoma (NHL), according to a new report from Kantar Health , a leading global healthcare consulting firm. MabThera is the only biologic available to treat diffuse large B-cell lymphoma (DLBCL), the most common form of NHL.

According to Kantar Health's report, "Biosimilars in China: Market Access and Barriers," the incidence of NHL in China has been growing and is expected to grow at an annual rate of 2.8 percent through 2030. According to physicians surveyed by Kantar Health, half of NHL patients are treated with MabThera, and 85 percent of DLBCL patients in China are eligible to receive MabThera, which is usually used in first-line treatment and will continue to be used if patients progress or relapse. Depending on the number of competitors on the market, MabThera could lose between half and three-quarters of its market share to biosimilars.

"Although MabThera is necessary to treat NHL, it is expensive, and there is a strong demand for more affordable options," said Maartje Van Diepen, Associate Director, Kantar Health. "Unfortunately, some technological barriers need to be overcome to produce MabThera's biosimilar. Despite this delay, almost all of the physicians we surveyed would welcome a biosimilar option because MabThera's price has not gone down in more than 10 years. NHL patients in China also are very sensitive to price changes and would accept a relatively low discount of 30 percent for the biosimilar."

Biosimilars also would be likely to take significant market share from biologics in breast cancer and metastatic colorectal cancer (mCRC). Herceptin (trastuzumab) is used as a first-line treatment for breast cancer and is widely accepted among HER2-positive patients. According to Kantar Health's research, biosimilars are expected to capture about 50 percent share from Herceptin.

"Since trastuzumab's efficacy in treating breast cancer is well accepted, its lower cost would cause it to steal share from Herceptin," Van Diepen said. "A patient assistance program could help narrow the gap between the originator and its biosimilars, assuming they have the same commercial conditions."

In mCRC Avastin (bevacizumab) is perceived by Chinese physicians to be not as efficacious as Erbitux (cetuximab) but is used more than Erbitux because of its lower price and wider patient scope. A biosimilar would potentially take more market share from Avastin (approximately 50 percent) than it would from Erbitux (about 12.5 percent).

Biologics are the recommended treatment for moderate and severe rheumatoid arthritis patients. The leading treatment is the biosimilar Yisaipu, while Humira (adalimumab) and Remicade (infliximab) are used in few patients. While biosimilars are used the most in rheumatoid arthritis, the market is dominated by local products rather than products from multinational corporations.

"Market conditions are unfavorable for foreign-produced biosimilars in rheumatoid arthritis," Van Diepen said. "The competition is fierce, with many domestic manufacturers producing or interested in producing biosimilars, and the low cost of Yisaipu means that patients are very price-sensitive and will be unlikely to switch without a large price discount."

About the Report

" Biosimilars in China: Market Access and Barriers " provides insights into market access, the competitive landscape, opportunities in key therapy areas and regulatory issues affecting the adoption of biosimilars in China. It offers a granular view of the local market through primary research and proprietary market data.

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit http://www.kantarhealth.com .

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/12/prweb12409024.htm

Kantar Health Stacy Sevcik +1 (314) 529-3062

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into Guess?, Inc.: Are Fiduciary Duties at Risk?

Updated Category News Views 121

Introduction to the Investigation Recently, a significant issue has arisen concerning Guess?, Inc. (NYSE: GES) and its handling of a pending merger with Authentic Brands Group LLC. This acquisition deal, valued at $16.75 per share, has prompted a legal investigation to determine whether the company's board of directors and top executives may have breached their fiduciary...

Continue Reading
Count Down to Class Action: Important News for GO Investors

Updated Category News Views 281

Important Deadline for Grocery Outlet Holding Corp. Investors As the deadline for the class action lawsuit approaches for Grocery Outlet Holding Corp. (NASDAQ: GO), investors are urged to pay close attention. The law firm Kessler Topaz Meltzer & Check, LLP has announced that investors who purchased or acquired Grocery Outlet securities from November 7, 2023, to May 7,...

Continue Reading
Discover KLIMB Jr.: The Latest in Pet Training Innovation

Updated Category News Views 239

Introducing the KLIMB Jr. by Blue-9 Pet Products Blue-9 Pet Products has made a remarkable stride in pet care with the introduction of the KLIMB Jr., a compact and versatile training platform for dogs and cats. This innovative product serves as a perfect tool for pet owners aiming to enhance their pets’ training and daily enrichment activities. A Tailored Solution for...

Continue Reading
Elsevier, Lancet Awards Highlight Community Health Impact

Updated Category News Views 62

Pioneering Health Awards Make Waves Amidst our swirling universe of breakthroughs and challenges, three research teams just snagged the spotlight. Recognized by the Elsevier Foundation and The Lancet in their first-ever Evidence to Impact Awards. These folks aren't just scribbling in labs—they're rolling up their sleeves and getting those much-needed health solutions...

Continue Reading
k-ID's Kai SDK: Age-Adaptive Design Revolution

Updated Category News Views 139

New Horizons for Developers Today, if you're building an app, you're just as likely to be wrangling with legal regulations as you are writing code. That's where k-ID’s new SDK, Kai, comes into play—it's not just another tool in the shed, it’s the whole toolbox for dealing with age-specific app requirements everywhere. The Changing App Landscape Why does this matter?...

Continue Reading